Cellectar Biosciences (CLRB) Projected to Post Quarterly Earnings on Wednesday

Cellectar Biosciences (NASDAQ:CLRB) is anticipated to post its quarterly earnings results before the market opens on Wednesday, March 26th. Analysts expect Cellectar Biosciences to post earnings of ($0.38) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Cellectar Biosciences Trading Down 2.9 %

Shares of Cellectar Biosciences stock opened at $0.37 on Monday. The stock’s fifty day moving average price is $0.29 and its 200-day moving average price is $1.09. The firm has a market cap of $17.00 million, a P/E ratio of -0.21 and a beta of 0.96. Cellectar Biosciences has a 12 month low of $0.22 and a 12 month high of $4.17.

Hedge Funds Weigh In On Cellectar Biosciences

An institutional investor recently raised its position in Cellectar Biosciences stock. Bank of America Corp DE lifted its position in Cellectar Biosciences, Inc. (NASDAQ:CLRB) by 25.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 206,783 shares of the biopharmaceutical company’s stock after buying an additional 41,704 shares during the period. Bank of America Corp DE owned approximately 0.45% of Cellectar Biosciences worth $62,000 as of its most recent SEC filing. 16.41% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

CLRB has been the topic of a number of research reports. StockNews.com initiated coverage on shares of Cellectar Biosciences in a research report on Tuesday, March 18th. They set a “sell” rating on the stock. LADENBURG THALM/SH SH started coverage on shares of Cellectar Biosciences in a report on Thursday, December 5th. They set a “buy” rating and a $13.00 price objective on the stock. Finally, Oppenheimer reissued a “market perform” rating on shares of Cellectar Biosciences in a research note on Wednesday, December 11th.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.